SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 3, 2003; DOI 10.1182/blood-2003-03-0880. This Article Full Text (PDF) All Versions of this Article: 2003-03-0880v1 102/8/2746    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schnittger, S. Articles by Kern, W. Search for Related Content PubMed PubMed Citation Articles by Schnittger, S. Articles by Kern, W. Social Bookmarking                   What's this? Submitted March 25, 2003 Accepted June 6, 2003 New score predicting for prognosis in PML-RARA-, AML1-ETO-, or CBFB-MYH11- positive acute myeloid leukemia based on quantification of fusion transcripts Susanne Schnittger*, Martin Weisser, Claudia Schoch, Wolfgang Hiddemann, Torsten Haferlach, and Wolfgang Kern Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians University of Muncih, University Hospital Grosshadern, Munich, Germany Clinical Cooperative Group Leukemia (GSF), National Research Centre for Environment and Health, Munich, Germany * Corresponding author; email: susanne.schnittger{at}med3.med.uni-muenchen.de. To evaluate the prognostic significance of quantitative PML-RARA-, AML1-ETO- and CBFB-MYH11-fusion transcripts expression real time PCR was used to analyze bone marrow samples of 349 such patients at diagnosis and 522 samples of 142 patients also during therapy (total analyses: n=859; median number of follow-up samples: 4 per patient; median duration of assessment: 12 months). Lower expression levels at diagnosis correlated with better overall and event free survival in all three leukemia subtypes. Combining the median expression ratio after consolidation therapy and the 75%-percentile of the expression ratio at diagnosis a new score was established that separates a group with 100% EFS from a significantly worse group (p<0.0001) in each of the three AML subgroups. Eight patients showed increasing levels of expression during follow up and all relapsed. In conclusion, patients at high risk of treatment failure can be identified by 1) high levels of fusion gene expression at diagnosis and /or 2) less than 3 logs of tumor reduction during the first 3-4 months of therapy. By the combination of the transcription ratios at these two checkpoints a new powerful prognostic score has been established. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Clozel, A. Renneville, M. Venot, C. Gardin, C. Kelaidi, G. Leroux, V. Eclache, C. Preudhomme, P. Fenaux, and L. Ades Slow relapse in acute myeloid leukemia with inv(16) or t(16;16) Haematologica, October 1, 2009; 94(10): 1466 - 1467. [Full Text] [PDF] S. Schnittger, W. Kern, C. Tschulik, T. Weiss, F. Dicker, B. Falini, C. Haferlach, and T. Haferlach Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML Blood, September 10, 2009; 114(11): 2220 - 2231. [Abstract] [Full Text] [PDF] D. Grimwade, J. V. Jovanovic, R. K. Hills, E. A. Nugent, Y. Patel, R. Flora, D. Diverio, K. Jones, H. Aslett, E. Batson, et al. Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy J. Clin. Oncol., August 1, 2009; 27(22): 3650 - 3658. [Abstract] [Full Text] [PDF] C. Santamaria, M. C. Chillon, R. Garcia-Sanz, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, F. Ramos, T. Bernal, J. A. Queizan, M. J. Penarrubia, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia Haematologica, December 1, 2008; 93(12): 1797 - 1805. [Abstract] [Full Text] [PDF] L. Maurillo, F. Buccisano, M. I. Del Principe, G. Del Poeta, A. Spagnoli, P. Panetta, E. Ammatuna, B. Neri, L. Ottaviani, C. Sarlo, et al. Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia J. Clin. Oncol., October 20, 2008; 26(30): 4944 - 4951. [Abstract] [Full Text] [PDF] U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients Blood, March 1, 2008; 111(5): 2527 - 2537. [Abstract] [Full Text] [PDF] V. P. S. Rawat, S. Thoene, V. M. Naidu, N. Arseni, B. Heilmeier, K. Metzeler, K. Petropoulos, A. Deshpande, L. Quintanilla-Martinez, S. K. Bohlander, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia Blood, January 1, 2008; 111(1): 309 - 319. [Abstract] [Full Text] [PDF] C. Santamaria, M. C. Chillon, C. Fernandez, P. Martin-Jimenez, A. Balanzategui, R. Garcia Sanz, J. F. San Miguel, and M.-G. Gonzalez Using quantification of the PML-RAR{alpha} transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia Haematologica, March 1, 2007; 92(3): 315 - 322. [Abstract] [Full Text] [PDF] S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] D. P. Kalogianni, V. Bravou, T. K. Christopoulos, P. C. Ioannou, and N. C. Zoumbos Dry-reagent disposable dipstick test for visual screening of seven leukemia-related chromosomal translocations Nucleic Acids Res., February 28, 2007; 35(4): e23 - e23. [Abstract] [Full Text] [PDF] S. Ghaffari, S Rostami, D Bashash, K Alimoghaddam, and A Ghavamzadeh Real-time PCR analysis of PML-RAR{alpha} in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy Ann. Onc., October 1, 2006; 17(10): 1553 - 1559. [Abstract] [Full Text] [PDF] U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger Implications of NRAS mutations in AML: a study of 2502 patients Blood, May 15, 2006; 107(10): 3847 - 3853. [Abstract] [Full Text] [PDF] H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al. High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia J. Clin. Oncol., April 1, 2006; 24(10): 1507 - 1515. [Abstract] [Full Text] [PDF] S. Schnittger, T. M. Kohl, T. Haferlach, W. Kern, W. Hiddemann, K. Spiekermann, and C. Schoch KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood, March 1, 2006; 107(5): 1791 - 1799. [Abstract] [Full Text] [PDF] F. Lo-Coco and E. Ammatuna The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment Hematology, January 1, 2006; 2006(1): 156 - 161. [Abstract] [Full Text] [PDF] S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF] T. Haferlach, A. Kohlmann, S. Schnittger, M. Dugas, W. Hiddemann, W. Kern, and C. Schoch Global approach to the diagnosis of leukemia using gene expression profiling Blood, August 15, 2005; 106(4): 1189 - 1198. [Abstract] [Full Text] [PDF] W. Kern, D. Voskova, C. Schoch, W. Hiddemann, S. Schnittger, and T. Haferlach Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia Blood, November 15, 2004; 104(10): 3078 - 3085. [Abstract] [Full Text] [PDF] P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs Clin. Chem., July 1, 2004; 50(7): 1165 - 1173. [Abstract] [Full Text] [PDF] Z.-X. Shen, Z.-Z. Shi, J. Fang, B.-W. Gu, J.-M. Li, Y.-M. Zhu, J.-Y. Shi, P.-Z. Zheng, H. Yan, Y.-F. Liu, et al. Inaugural Article: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia PNAS, April 13, 2004; 101(15): 5328 - 5335. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020